Moving from painkillers to a cannabis-based pain plan
Moving from painkillers to a cannabis regimen can involve reducing opioid use, adding a complementary symptom treatment, or carefully replacing one medicine with another. For people living with cancer or persistent pain, a planned transition is safer than making several changes at once. Cannabis may help some people manage pain, nausea, sleep disturbance or anxiety, but responses vary and evidence for cancer-related pain remains limited. It has not been shown to treat cancer itself, so anti-cancer treatment should continue as directed.
A useful transition begins with a clear assessment of pain, function, medication effects and personal priorities. The goal may be fewer opioid side effects, better sleep, more comfortable movement or reduced breakthrough pain rather than complete elimination of conventional medication. Cannabis works differently from opioids, has no reliable opioid-equivalent dose and can cause its own harms. A GP, specialist, pharmacist and other members of the healthcare team can help determine whether cannabis is appropriate and how safely to incorporate it.
Start with a clear picture of pain and medication
Keep a short daily record of pain intensity, where it occurs, what relieves it and how it affects walking, work, sleep or family activities. Include prescription medicines, over-the-counter products, supplements, alcohol and recreational substances. A record of actual function is more useful than a single pain score, because it shows whether the current regimen is improving the outcomes that matter.
Opioids can be highly effective for certain types of severe pain, but long-term use may cause constipation, nausea, sedation, hormonal changes, impaired concentration and physical dependence. Tolerance can also develop, leading to a need for higher doses without necessarily receiving better pain relief. These risks do not mean opioids should be stopped suddenly; withdrawal can worsen pain, sleep and mood, particularly after prolonged use.
Make an inventory before attending the appointment. Request an updated medication list from the GP and pharmacist, and identify who is prescribing each medicine. Any medicines that cause withdrawal when reduced, such as opioids, benzodiazepines or certain antidepressants, need a clinician-guided plan. New or sudden severe pain should be assessed rather than assumed to be the usual cancer pain; infection, fractures, spinal compression or blood clots can require urgent treatment.
Plan the change with the people prescribing treatment
Arrange a review with the clinician responsible for the painkillers, ideally alongside someone experienced in medicinal cannabis. Bring the medication list, symptom diary and questions about interactions, driving, work and home responsibilities. Explain what you hope to achieve and what has already been tried. A pain specialist or palliative-care clinician may be useful when pain is complex or cancer treatment is ongoing.
Do not stop or substitute painkillers independently. A responsible transition usually keeps the existing pain plan stable while a cannabis product is introduced at a conservative dose. If opioid reduction is appropriate, the prescriber may gradually reduce the dose or frequency while monitoring withdrawal, pain and function. Some people taper more slowly than others, and there is no fixed schedule suitable for every patient.
Cannabis should not be treated as a guaranteed opioid replacement. Studies suggest it may reduce pain or improve some quality-of-life measures in selected patients, but results are inconsistent. While waiting for an appointment, entertainment can help pass the time, although material about online poker freerolls is no substitute for medical care and may create additional gambling problems for some adults.
Choose a lawful product and administration method
In Australia, cannabis-derived products are regulated through the Therapeutic Goods Administration. Most medicinal cannabis medicines, including THC-containing preparations, are Schedule 8 prescription medicines. Certain low-THC CBD products may fall under Schedule 4, but the exact classification and access requirements should be checked against current TGA rules. Products from an overseas website should never be assumed to be lawful, safe or suitable for supply in Australia.
Start with a precise understanding of what each product contains. CBD alone does not create the same effects as THC, while products containing THC can cause intoxication, anxiety, impaired coordination and slower reaction time. Ask for the labelled active ingredients, concentrations and dosing directions, and use a product from a lawful supply route. Quality controls, tamper-evident packaging and batch testing can help identify products that match their labels.
The administration route also matters. Oral or sublingual cannabis oils are absorbed through the digestive system or beneath the tongue and have a delayed effect that can be difficult to judge. Products intended for rectal use may be considered when swallowing is difficult, but only a product specifically made for that route should be used; household oils and unmeasured concentrates should not be improvised for rectal administration. A pharmacist can check product instructions and explain how different formulations are used.
Use a cautious dosing and monitoring process
Follow the prescription or product directions rather than relying on a universal cannabis dose. If the prescriber recommends titration, increase one product at a time and allow enough time to judge the effect. Keeping a simple diary of dose, timing, pain, sleep, mood and adverse effects helps reveal whether a symptom is improving and whether the amount is becoming excessive. Changes to several products at once make the outcome difficult to interpret.
CBD can interact with medicines, including some anticonvulsants, antidepressants, anticoagulants and sedatives. THC can add to drowsiness caused by opioids, alcohol, antihistamines or sleeping tablets. People taking cancer medicines should ask the oncologist and pharmacist to check for interactions before starting a cannabis product. Liver function may need monitoring in certain circumstances, particularly with higher doses, pre-existing liver disease or medicines that affect the same metabolic pathways.
Cannabis is unsuitable for everyone. A clinician should review pregnancy, breast-feeding, cardiovascular disease, psychosis, bipolar disorder, a history of substance dependence and current driving or machinery responsibilities. Seek urgent help for severe breathing difficulty, chest pain, collapse, confusion, hallucinations or uncontrolled vomiting. In Australia, call 000 for an emergency. Cannabis may also increase sedation and falls risk, so it should not be combined with alcohol or used before driving; impairment and road rules differ across states and territories.
Fit cannabis into everyday pain management
Pain is rarely improved by medication alone. A combined plan may include paced activity, gentle exercise, physiotherapy, heat or cold, suitable positioning, sleep routines, psychological support and treatment of the underlying condition. Cannabis can support sleep or reduce muscle tension for some people, but using more solely to obtain sedation may lead to tolerance, dependence and daytime impairment. Occupational therapy may help with practical tasks, while a psychologist can assist with the distress that often accompanies persistent illness.
Cancer-related symptoms may involve more than pain. Nausea, appetite changes, anxiety, fatigue and disrupted sleep can affect each other, so each symptom needs its own assessment. Cannabis preparations are sometimes considered for nausea or sleep, yet conventional anti-nausea medicines and supportive care remain important. Any use during chemotherapy or radiation should be coordinated with the treating team rather than added as a stand-alone remedy.
Stress and reduced mobility can also increase financial and social isolation. During a vulnerable period, promotions advertised as casino free spins should be approached carefully, particularly by people who already gamble heavily or use substances to escape discomfort. Practical alternatives include a walking plan, gentle yoga, a crafts activity, contact with a support group or scheduled time with friends. Anyone whose gambling is becoming harmful can seek confidential help from a gambling support service.
Build a support, cost and follow-up system
Regular review is essential because pain, treatment side effects and cannabis response can change. A useful follow-up should review the diary, medicine supply, withdrawal symptoms, sleep, mood, function and safety concerns. Keep the plan written so that family members, the GP and pharmacist understand the intended doses and when to seek urgent advice. Reassess if cancer treatment changes, another medicine is added or the original pain goal is no longer being met.
Australia’s healthcare system creates several practical considerations. An eligible GP consultation may receive a Medicare rebate, although medicinal cannabis products can still involve substantial out-of-pocket costs and may not be covered by the Pharmaceutical Benefits Scheme. Telehealth can improve access for people in regional areas or outside major cities such as Sydney, Melbourne and Brisbane, while prescriptions can generally be dispensed through a local pharmacy or chemist. A pharmacist can also check storage requirements and help with lawful supply arrangements.
Patients and families can contact CBD International’s patient support to learn about its cannabis oil formulations, application review and ongoing support services. This can help clarify questions before consulting an Australian prescriber, but it should complement, not replace, local medical advice. Australian patients should verify TGA requirements, obtain any necessary prescription and use lawful supply channels. Support is also available through Cancer Council Australia on 13 11 20, which can provide information and connect patients with local cancer and pain services.
Your next step is to book a medication review with your GP and bring a complete list of painkillers, supplements and current symptoms. Ask specifically how cannabis could be introduced, which product and route are appropriate, what should be monitored and how any opioid reduction would be staged. Agree on written goals, review dates and clear safety thresholds before collecting the first product.
Keep the first phase simple: one authorised product, the lowest clinician-advised dose, careful observation and no abrupt change to other medicines. Record what changes in pain and function, and arrange follow-up before making further adjustments. This creates a transition that can be reviewed, modified and stopped safely if cannabis is not providing meaningful benefit.